Journal article
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine plus FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 trial)
Clinical cancer research, Vol.14(13), pp.4192-4199
07/01/2008
DOI: 10.1158/1078-0432.CCR-07-5278
PMID: 18593999
Abstract
Purpose: GOLFIG chemoimmunotherapy regimen proved to be a safe and very active chemoimmunotherapy regimen in advanced colon cancer patients. We have thus investigated the immunobiological feedback to the treatment and its possible correlation with the clinical outcome of these patients.
Experimental Design:This clinical and immunologic study involved 46 patients, 27 males and 19 females, enrolled in the GOLFIG-1 phase II trial who received gemcitabine (1,000 mg/m(2) on days 1 and 15), oxaliplatin (85 mg/m(2) on days 2 and 16), levofolinic acid (100 mg/m(2) on days 1, 2, 15, and 16), and 5-fluorouracil (400 mg/m(2) as a bolus, and 800 mg/m2 as a 24-hour infusion on days 1, 2, 15, and 16) followed by s.c. granulocyte macrophage colony-stimulating factor (100 mu g, on days 3-7) and interleukin 2 (0.5 x 10(6) IU twice a day on days 8-14 and 17-29).
Results: The regimen was confirmed to be safe and very active in pretreated patients with metastatic colorectal cancer. A subgroup analysis of these patients revealed a prolonged time to progression and survival in six patients who developed late signs of autoimmunity. A multivariate analysis validated the occurrence of autoimmunity signs as an independent predictor of favorable outcome. A parallel immunologic study detected in the peripheral blood mononuclear cells of these patients a progressive increase in lymphocyte and eosinophil counts, amplification in central memory, a marked depletion of immunosuppressive regulatory T cells, and activation of colon cancer-specific cytotoxic T cells.
Conclusions: Our results suggest that immunity feedback to GOLFIG regimen and its antitumor activity are tightly correlated.
Details
- Title: Subtitle
- Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine plus FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 trial)
- Creators
- Pierpaolo Correale - University of SienaPierosandro Tagliaferri - Magna Graecia UniversityAntonella Fioravanti - Indian Immunologicals (India)Maria Teresa Del Vecchio - University of SienaCinzia Remondo - University of SienaFrancesco Montagnani - University of SienaMaria Saveria Rotundo - Magna Graecia UniversityChiara Ginanneschi - University of SienaIgnazio Martellucci - University of SienaEdoardo Francini - University of SienaMaria Grazia Cusi - University of SienaPierfrancesco Tassone - Magna Graecia UniversityGuido Francini - University of Siena
- Resource Type
- Journal article
- Publication Details
- Clinical cancer research, Vol.14(13), pp.4192-4199
- DOI
- 10.1158/1078-0432.CCR-07-5278
- PMID
- 18593999
- ISSN
- 1078-0432
- eISSN
- 1557-3265
- Publisher
- Amer Assoc Cancer Research
- Number of pages
- 8
- Language
- English
- Date published
- 07/01/2008
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221143002771
Metrics
1 Record Views